Marker Therapeutics, Inc.
NCM: MRKRLive Quote
📈 ZcoreAI Score
Our AI model analyzes Marker Therapeutics, Inc.'s price action across multiple timeframes using regression channels and statistical scoring.
Get MRKR Z-Score →About Marker Therapeutics, Inc.
Healthcare
Biotechnology
Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, develops and commercializes T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications in the United States. The company's multi antigen recognizing (MAR)-T cell therapy technology is based on the selective expansion of non-engineered tumor-specific T cells that recognize tumor-associated antigens and kill tumor cells expressing those targets. It develops MT-601, which is in Phase 1 trials for the treatment of lymphoma and pancreatic cancer; and MT-401-OTS, which is in a Phase 1 trial for the treatment of acute myeloid leukemia and myelodysplastic syndromes. The company was formerly known as TapImmune, Inc. and changed its name to Marker Therapeutics, Inc. in October 2018. Marker Therapeutics, Inc. was founded in 1999 and is headquartered in Houston, Texas.
📊 Fundamental Analysis
Marker Therapeutics, Inc. demonstrates a profit margin of 0.0%, which is below the sector average, suggesting competitive pressure.
The company recently reported -51.0% revenue growth, which is negative, indicating a recent decline in revenue.
Return on Equity (ROE) is -68.8%, which indicates that capital utilization is currently under pressure.
At a current price of $1.75, MRKR currently sits at the 29th percentile of its 52-week range (Range: $0.81 - $4.07).
🏥 Financial Health
🔴
Profit Margin
Weak
🔴
Revenue Growth
Weak
🔴
Return on Equity
Weak
🔴
Beta (Risk)
High Volatility
Key Financials
Market Cap
$29.18M
Trailing P/E
--
Forward P/E
-9.21
Beta (5Y)
1.47
52W High
$4.07
52W Low
$0.81
Avg Volume
231K
Day High
Day Low